RX-3117: "Of 31 evaluable patients, 19% had disease control at 4 months, 1 complete response (CR) with patient continuing treatment after 14 months, 5 patients with stable disease (SD) ≥ 4 months"; Urothelial Cancer

fluorocyclopentenylcytosine (RX-3117) - Rexahn

Feb 16, 2019